

Curriculum Vitae



Liang Han MD, Chief Doctor, Professor

Education & Training

- German Language Institute, Beijing Foreign Language University, 1991-1992
- Guest Doctor, Department of General Surgery, State Hospital St. Gallen, Switzerland, 1992-1994
- Visiting Fellow, MDC Molecular Medical Center, Roberet-roessle Clinic, Charite, Humboldt University of Berlin, Germany, 1999-2000
- Visiting Fellow, MD Anderson Cancer Center, Huston, Texas, USA, 2007
- MD, Medical Faculty, Tianjin Medical College, Tianjin 1980-1985

Current Positions

- Director of Gastrointestinal Oncological Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. Chief Doctor, Professor of Tianjin Medical University. 2004.

Previous Professional Experiences

- Director of Gastric Cancer Surgical Department, Tianjin Medical University Cancer Institute & Hospital, 2004-2016
- Deputy Director of Gastrointestinal Oncological Surgery, Tianjin Medical University Cancer Institute and Hospital, Chief Doctor, 2000-2004.
- Deputy-Chief Doctor, Department of Abdominal Oncology, Tianjin Medical University Cancer Institute and Hospital, 1995-2000.
- Resident, Department of Abdominal Oncology, Tianjin Cancer Hospital, 1985-1995

Board Certification

- Members of Board, Chinese Anti-Cancer Association, 1997,
- Members of Chinese Medical Association, 1990,
- President-elect, Chinese Gastric Cancer Association, 2018,
- Vice-President of Gastric Cancer Committee, Chinese Medical Association, 2013

- President-elect, Surgical Oncologic Committee, Chinese Doctor's Association, 2014
- Member of International Gastric Association

Recent key publications (2014-present)

1. Deng JY, Zhang RP, Pan Y, Wang BG, Wu LL, Jiao XG, Bao T, Hao XS, **Liang H**. Comparison of the staging of regional lymph nodes using the sixth and seventh editions of the TNM classification system for the evaluation of overall survival in gastric cancer patients: findings of a case-control analysis involving a single institute in China. *Surgery* 2014; 156(1):64-74
2. Deng JY, Zhang RP, **Liang H**, et al. Methylated CpG site count of dapper homolog 1 (DACT1) promoter prediction the poor survival of gastric cancer. *Am J Cancer Res* 2014;4(5):518-27
3. Deng JY, Zhang R, Jiang N, **Liang H**, et al. Superior of the ratio between negative and positive LN for predicting the prognosis for patients with GC. *Ann Surg Oncol* 2014; DOI 10.1245/s10434-014-4128-8
4. Deng JY, Jiang N, Liu Hong G, **Liang H**. Clinical significance of the methylated cytosine-phosphate-guanine sites of protocadherin-10 promoter for evaluating the prognosis of gastric cancer. *J Am Coll Surg* 2014 Jun 26. Pii: S1072-7515(14)00502-X
5. Deng JY, Zhang RP, Pan Y, Ding XW, Cai MZ, Liu Y, Liu HG, Bao T, Jiao XG, Hao XS, **Liang H**. Tumor size as a recommendable variable for accuracy of the prognostic prediction of gastric cancer: a retrospective analysis of 1521 patients. *Ann Surg Oncol* 2014; Aug 26, doi:10.1245/s10434-014-4014-x
6. Deng JY, Liu H, Liang Y, **Liang H**, et al. Methylation of ras association domain protein 10 promoter negative association with the survival of gastric cancer. *Am J Cancer Res* 2014;4(6):916-23
7. Jiang N, Deng JY, **Liang H**, et al. Node-extranodal soft tissue stage based on extranodal metastasis is associated with poor prognosis of patients with gastric cancer. *J Surg Res* 2014;192(1):90-7
8. Jiao XG, Deng JY, Wang XN, **Liang H**. Prognostic value of number of examined lymph nodes in patients with node-negative gastric cancer. *J Gastroenterol.* 2014 Apr 7;20(13):3640-8.
9. Liang Y, Deng JY, **Liang H**, et al. The positive impact of surgeon specialization on survival for gastric cancer patients with curative intent. *Gastric Cancer.* 2014 Oct 15. [Epub ahead of print] PMID:25315086
10. Jiang N, Deng J, **Liang H**, et al. Tumor volume as a prognostic factor was superior to the seventh edition of the pT classification in resectable gastric cancer. *Eur J Surg Oncol.* 2015;41(3):315-22.
11. Yuexiang Liang. Positive impact of adding No.14v lymph node to D2 dissection
12. on survival for distal gastric cancer patients after surgery with curative intent. *Chin J*

Cancer Res 2015;27(6):580-587

13. Deng JY, Jiang N, Jiao XG, **Liang H**, et al. Tumor size as a recommendable variable for accuracy of the prognostic prediction of gastric cancer: A retrospective analysis of 1521 patients. *Ann Surg Oncol* 2015;22:565-572
14. Liu HG, Liu Y, Kong FM, Xin W, Li XJ, **Liang H**. Elevated levels of SMYD3 are correlated with over-expression of Transforming growth factor-beta1 in gastric cancer. *J Am Coll Surg* 2015 doi:10.1016/j.jamcollsurg.2015.02.023.
15. Deng J, Zhang R, Hou Y, Liu Y, Ying G, Pan Y, Hao X, **Liang H**. Clinical and experimental role of ring finger protein 180 on lymph node metastasis and survival gastric cancer. *Brit J Surg* 2016;103:407-416.
16. Deng JY, Yamashita H, Seto Y, **Liang H**. Increasing the number of examined lymph nodes is a prerequisite for improvement in the accurate evaluation of overall survival of node-negative gastric cancer patients. *Ann Surg Oncol* 2016;Oct 21doi:10.1245/s10434-016-5513-8
17. **Liang H**, Deng JY. Evaluation of rational extent lymphadenectomy for local advanced gastric cancer. *Chin J Cancer Res* 2016;28(4):397-403
18. Yamashita H, Deng J, Liang H, Seto Y. Re-evaluating the prognostic validity of the negative to positive lymph node ratio in node-positive gastric cancer patients. *Surgery* 2017 161(6):1588-1596. doi: 10.1016/j.surg.2016.12.018
19. Deng JY, Liang H. Prognostic value of the cancer oncogene Kelch-like 6 in gastric cancer. *Br J Surg*. 2017 Dec; 104 (13): 1847-1856.
20. Jiangtao Guo, Jingyu Deng, Liang H. Effect of the number of positive nodules in extranodal soft tissues on the overall survival of gastric cancer patients. *Int Clin Exp Pathol* 2017;10(11):11090-11097.
21. Deng JY, Yamashita H, Yasuyuki Seto, Liang H. Increasing the number of examined lymph nodes is prerequisite for improvement in the accurate evaluation of overall survival of node-negative gastric cancer. *Ann Surg Oncol*. 2017;24(3):745-753
22. Wu LL, Zhang C, Liang YX, et al. Risk factors for metastasis to No.14v lymph node and prognostic value of 14v status for gastric cancer patients after surgery. *Jap JCO* 2018;1-8.doi:10.1093/jjco/hyy006.
23. Deng JY, Liu Jingyuan, Wang Wei, et al. Validation of clinical significance of examined lymph nodes count for the accurate prognostic evaluation of gastric cancer for the eighth edition of the American Joint Committee on Cancer (AJCC) TNM staging system. *Chin J Cancer Res*. 2018;30(5):1-15.
24. Wang W, Sun Z, Deng JY, Seeruttun SR, Wang ZN, Xu HM, Liang H, Zhou ZW. A novel nomogram individually predicting disease-specific survival after D2 gastrectomy for advanced gastric cancer. *Cancer Commun(Lond)*. 2018;38(1):23. Doi:10.1186/s40880-018-0293-0
25. Fang C, Wang W, Deng JY, et al. Proposal and validation of a modified staging system to improve the prognosis predictive performance of the 8th AJCC/UICC pTNM staging system for gastric adenocarcinoma: a multicenter study with external validation. *Cancer Commun(Lond)*. 2018;38(1):67.doi:10.1186/s40880-018-0337-5.
26. Wang P, Sun Z, Wang W, Deng JY, Wang Z, Liang H, Zhou Z, Xu H. Conditional survival of patients with gastric cancer who undergo curative resection: A

multiinstitutional analysis in China. *Cancer*. 2018;124(5):916-924.
Doi:10.1002/cncr.31160.

27. Shi YN, Li Y, Wang LP, Wang ZH, Liang XB, Liang H, Zhang L, Li B, Zhao Q, Ma ZX, Zhao XF, Zhang ZD, Liu Y, Tan BB, Wang D, Wang LL, Hao YJ, Jia N. Gastrointestinal stromal tumor (GIST) with liver metastases: An 18 year experience from the GIST cooperation group in North China. *Medicine (Baltimore)*. 2017;96(46): e8240.doi: 10.1097.MD.00000000000008240.